TY - JOUR
T1 - Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung
AU - Tomaki, Masafumi
AU - Sugiura, Hisatoshi
AU - Koarai, Akira
AU - Komaki, Yuichi
AU - Akita, Takefumi
AU - Matsumoto, Tatsumi
AU - Nakanishi, Atsushi
AU - Ogawa, Hiromasa
AU - Hattori, Toshio
AU - Ichinose, Masakazu
PY - 2007/10
Y1 - 2007/10
N2 - The involvement of inflammation in the pathogenesis of chronic obstructive pulmonary disease (COPD) has been investigated using samples from relatively central airways such as airway biopsies, but there have been fewer studies in the peripheral lung, which is thought to be the main site of the disease process. To determine the molecules that relate to the mechanisms underlying the pathogenesis of COPD, we evaluated the mRNA expression of inflammatory cytokines, chemokines, oxidant enzymes, antioxidant enzymes, proteinases and antiproteinases in peripheral lung tissues from 33 COPD and non-COPD subjects who were undergoing lung resection for lung cancer using an RT-PCR technique. Among the 42 studied candidate genes, the expressions of mRNA for catalase, glutathion S-transferase P1 (GSTP1), glutathion S-transferase M1 (GSTM1), microsomal epoxide hydrolase (mEPHX) and tissue inhibitor of metalloproteinase 2 (TIMP2) were significantly decreased in COPD lung tissues compared with those in non-COPD tissues, and most of these decreases were significantly correlated with the degree of airflow limitation. On the other hand, the expressions of mRNA for interleukin 1β (IL-1β), interleukin 8 (IL-8), growth-related oncogene-α (Gro-α) and monocyte chemotactic protein-1 (MCP-1) were significantly increased in COPD lungs. Most of these changes were also associated with cigarette smoking. These data suggest that an impairment of protective mechanisms against oxidants and xenobiotics, in addition to the upregulation of CXC- and CC-chemokines, may be associated with cigarette smoking and involved in the inflammatory process of COPD.
AB - The involvement of inflammation in the pathogenesis of chronic obstructive pulmonary disease (COPD) has been investigated using samples from relatively central airways such as airway biopsies, but there have been fewer studies in the peripheral lung, which is thought to be the main site of the disease process. To determine the molecules that relate to the mechanisms underlying the pathogenesis of COPD, we evaluated the mRNA expression of inflammatory cytokines, chemokines, oxidant enzymes, antioxidant enzymes, proteinases and antiproteinases in peripheral lung tissues from 33 COPD and non-COPD subjects who were undergoing lung resection for lung cancer using an RT-PCR technique. Among the 42 studied candidate genes, the expressions of mRNA for catalase, glutathion S-transferase P1 (GSTP1), glutathion S-transferase M1 (GSTM1), microsomal epoxide hydrolase (mEPHX) and tissue inhibitor of metalloproteinase 2 (TIMP2) were significantly decreased in COPD lung tissues compared with those in non-COPD tissues, and most of these decreases were significantly correlated with the degree of airflow limitation. On the other hand, the expressions of mRNA for interleukin 1β (IL-1β), interleukin 8 (IL-8), growth-related oncogene-α (Gro-α) and monocyte chemotactic protein-1 (MCP-1) were significantly increased in COPD lungs. Most of these changes were also associated with cigarette smoking. These data suggest that an impairment of protective mechanisms against oxidants and xenobiotics, in addition to the upregulation of CXC- and CC-chemokines, may be associated with cigarette smoking and involved in the inflammatory process of COPD.
KW - Catalase
KW - Glutathion S-transferase M1
KW - Glutathion S-transferase P1
KW - Microsomal epoxide hydrolase
KW - RT-PCR
KW - Tissue inhibitor of metalloproteinase 2
KW - mRNA
UR - http://www.scopus.com/inward/record.url?scp=34447537656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447537656&partnerID=8YFLogxK
U2 - 10.1016/j.pupt.2006.06.006
DO - 10.1016/j.pupt.2006.06.006
M3 - Article
C2 - 16919984
AN - SCOPUS:34447537656
SN - 1094-5539
VL - 20
SP - 596
EP - 605
JO - Pulmonary Pharmacology and Therapeutics
JF - Pulmonary Pharmacology and Therapeutics
IS - 5
ER -